Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Garofalo Health Care SpAMIL:GHC +0.36%90 3-Year EBITDA Growth Rate is 13.50% as of Mar. 2026, which is 11% below its 10-year median of 15.20. GuruFocus rates MIL:GHC with a GF Score™ of 90/100 and a GF Value™ of €6.09 (Fairly Valued). The stock has 5 warning signs investors should review. Among 527 Healthcare Providers & Services companies, Garofalo Health Care SpA ranks better than 56.74% on this metric.
During the past 12 months, Garofalo Health Care SpA's average EBITDA Per Share Growth Rate was 0.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Garofalo Health Care SpA was 27.20% per year. The lowest was -5.40% per year. And the median was 15.20% per year.
Garofalo Health Care SpA (MIL:GHC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Garofalo Health Care SpA 3-Year EBITDA Growth Rate Related Terms
MIL:GHC vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Garofalo Health Care SpA's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Garofalo Health Care SpA 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Garofalo Health Care SpA's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Garofalo Health Care SpA's 3-Year EBITDA Growth Rate falls into.
Garofalo Health Care SpA 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.50% mean?
Garofalo Health Care SpA (MIL:GHC) has a 3-Year EBITDA Growth Rate of 13.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Garofalo Health Care SpA and its competitors. This is 11% below median its historical median of 15.20. According to the industry distribution chart, Garofalo Health Care SpA ranks #228 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 43.3%.
Is Garofalo Health Care SpA's 3-Year EBITDA Growth Rate too high?
Garofalo Health Care SpA's current 3-Year EBITDA Growth Rate of 13.50% is 11% below median its 10-year median of 15.20. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Garofalo Health Care SpA's value of 13.50% is 32.4% above this industry median. Based on the distribution chart, Garofalo Health Care SpA ranks #228 out of 527 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Garofalo Health Care SpA has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Garofalo Health Care SpA's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Garofalo Health Care SpA ranks #228 out of 527 companies for 3-Year EBITDA Growth Rate. This puts Garofalo Health Care SpA in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Garofalo Health Care SpA's value of 13.50% is 32.4% above this benchmark. While the company's 10-year median is 15.20 vs. the industry median of 10.20, Garofalo Health Care SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Garofalo Health Care SpA's current 3-Year EBITDA Growth Rate of 13.50% is 32.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Garofalo Health Care SpA and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Garofalo Health Care SpA's current 3-Year EBITDA Growth Rate is 13.50%, which is 11% below median its own 10-year median of 15.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Garofalo Health Care SpA stock overvalued right now?
Based on GuruFocus' analysis, Garofalo Health Care SpA (MIL:GHC) is currently considered Fairly Valued. The stock's GF Value™ is €6.09, compared to a current price of €5.64 — trading 7.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.50%, which is 11% below median its 10-year median of 15.20 and 32.4% above the Healthcare Providers & Services industry median of 10.20. Garofalo Health Care SpA's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Garofalo Health Care SpA (MIL:GHC), the current 3-Year EBITDA Growth Rate is 13.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Garofalo Health Care SpA (MIL:GHC) Overvalued in 2026?
Based on GuruFocus' analysis, Garofalo Health Care SpA stock appears to be undervalued.
The current stock price of €5.64 is trading 7.4% below its estimated GF Value™ of €6.09.
GuruFocus considers Garofalo Health Care SpA to be Fairly Valued.
Key valuation signals for MIL:GHC:
3-Year EBITDA Growth Rate: 13.50% (11% below median its 10-year median of 15.20)
GF Value™: €6.09 vs. price of €5.64 (7.4% below fair value)
Industry Position: 32.4% above the Healthcare Providers & Services median (#228 of 527)
No single metric tells the full story. See the MIL:GHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Garofalo Health Care SpA is an Italian accredited private healthcare provider offering a comprehensive range of services across various areas of healthcare through diversified specialties, supported by the use of technologies and qualified personnel. The Group mainly operates in regions of northern and central Italy, which have been selected based on their attractiveness in terms of per capita healthcare spending, above-average per capita income, and well-developed internal transport infrastructure.
90GF Score
Get the complete analysis for MIL:GHC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:GHC has been successfully added to your 
